Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2003-01-21
2004-11-16
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S178000, C514S824000
Reexamination Certificate
active
06818636
ABSTRACT:
The use of naturally occurring estrogenic compositions of substantial purity and low toxicity such as PREMARIN (conjugated equine estrogens) has become a preferred medical treatment for alleviating the symptoms of menopausal syndrome, osteoporosis/osteopenia in estrogen deficient women and in other hormone related disorders. The estrogenic components of the naturally occurring estrogenic compositions have been generally identified as sulfate esters of estrone, equilin, equilenin, 17-&bgr;-estradiol, dihydroequilenin and 17-&bgr;-dihydroequilenin-(U.S. Pat. No. 2,834,712). The estrogenic compositions are usually buffered or stabilized with alkali metal salts of organic or inorganic acids at a substantially neutral pH of about 6.5 to 7.5. Urea has also been used as a stabilizer (U.S. Pat. No. 3,608,077). The incorporation of antioxidants to stabilize synthetic conjugated estrogens and the failure of pH control with tris(hydroxymethyl)aminomethane (TRIS) to prevent hydrolysis is discussed in U.S. Pat. No. 4,154,820.
One of the compounds described herein, 3&bgr;-hydroxy-5,7,9-estratriene-17-one 3-sulfate ester sodium salt is a minor component of PREMARIN (conjugated equine estrogens). The preparation of 3&bgr;-hydroxy-5,7,9-estratriene-17-one is been disclosed by D. Banerjee in Ind. Chim. Belge. Suppl. 2: 435 (1959); however, no utility is provided for this compound.
REFERENCES:
patent: 2834712 (1958-05-01), Beall et al.
patent: 3608077 (1971-09-01), Ginsig
patent: 4154820 (1979-05-01), Simons
patent: 5545635 (1996-08-01), Bryant et al.
patent: 635781 (1936-10-01), None
patent: 864231 (1961-03-01), None
Physician Desk Reference, 48thEdition, pp. 2594-2596, 1994.*
Goodman and Gilman, Seventh Edition, pp. 1420-1429, 1985.*
Banerjee, D.K., et al., Indian J. Chem, 1969, 7 pp. 529-532.
Chem Abstract, CA64:11509a.
Chem Abstract, CA65:2576b.
Chem Abstract, CA54:9030h.
Johnson, R. et al., J. Pharma. Sci., 67(9), Sep. 1978, pp. 1218-1224.
Junghans, K., et al., Chem. Ber., 112(7), 1979, pp. 2631-2639.
Chemical Abstracts, 106(25), Jun. 22, 1987, No. 207882.
Chemical Abstracts, 6(21), May 22, 1967, No. 92028.
Kocovsky, P., et al., Coll. of Czechos. Chem. Communic., 39(7), 1974, pp. 1905-1913.
Bachmann, W.E. et al., Helv. Chim. Acta., 42(6), Oct. 15, 1959, pp. 1790-1793.
Eimasry, A.H., et al., J. Pharm. Sci., 59(4), Apr. 1970, pp. 449-458.
Schuller, W.H., et al., J. Med. Chem., 14(5), May 1971, p. 466.
Peters, R.H., et al., J. Med. Chem. 32(7), Jul. 1989, pp. 1642-1652.
Physicians Desk Reference, 48thedition, pp. 2594-2596, 1994.
Goodman and Gilman, seventh edition, pp. 1420-1429, 1985.
Starka et al., Chem. Abstract, CA64:11509a, 1966.
Starka et al., Chem. Abstract, CA65:2576b, 1966.
Kagan Michael Z.
Raveendranath Panolil
Shah Syed M.
Badio Barbara P.
Milowsky, Esq. Arnold S.
O'Connor Cozen
Wyeth
LandOfFree
B-ring estratrienes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B-ring estratrienes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B-ring estratrienes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3307390